These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 11103798

  • 21. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.
    Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J, Randlev B, Heise C, Uprichard M, Hatfield M, Rome L, Rubin J, Kirn D.
    Cancer Res; 2002 Nov 01; 62(21):6070-9. PubMed ID: 12414631
    [Abstract] [Full Text] [Related]

  • 22. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?
    Kirn D.
    Gene Ther; 2001 Jan 01; 8(2):89-98. PubMed ID: 11313778
    [Abstract] [Full Text] [Related]

  • 23. A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience).
    Lamont JP, Nemunaitis J, Kuhn JA, Landers SA, McCarty TM.
    Ann Surg Oncol; 2000 Sep 01; 7(8):588-92. PubMed ID: 11005557
    [Abstract] [Full Text] [Related]

  • 24. A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma.
    Villaret D, Glisson B, Kenady D, Hanna E, Carey M, Gleich L, Yoo GH, Futran N, Hung MC, Anklesaria P, Heald AE.
    Head Neck; 2002 Jul 01; 24(7):661-9. PubMed ID: 12112540
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy.
    Kim J, Cho JY, Kim JH, Jung KC, Yun CO.
    Cancer Gene Ther; 2002 Sep 01; 9(9):725-36. PubMed ID: 12189522
    [Abstract] [Full Text] [Related]

  • 26. [Gene therapy and molecular therapeutic for head and neck cancer].
    Tanaka H.
    Gan To Kagaku Ryoho; 2005 Dec 01; 32(13):2046-51. PubMed ID: 16352927
    [Abstract] [Full Text] [Related]

  • 27. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients.
    You L, Yang CT, Jablons DM.
    Cancer Res; 2000 Feb 15; 60(4):1009-13. PubMed ID: 10706117
    [Abstract] [Full Text] [Related]

  • 28. Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015.
    McCormick F.
    Semin Cancer Biol; 2000 Dec 15; 10(6):453-9. PubMed ID: 11170867
    [Abstract] [Full Text] [Related]

  • 29. E1B-deleted adenovirus replicates in p53-deficient lung cancer cells due to the absence of apoptosis.
    Harada N, Maniwa Y, Yoshimura M, Nagata M, Hamada H, Yokono K, Okita Y.
    Oncol Rep; 2005 Nov 15; 14(5):1155-63. PubMed ID: 16211279
    [Abstract] [Full Text] [Related]

  • 30. A novel E1A-E1B mutant adenovirus induces glioma regression in vivo.
    Gomez-Manzano C, Balague C, Alemany R, Lemoine MG, Mitlianga P, Jiang H, Khan A, Alonso M, Lang FF, Conrad CA, Liu TJ, Bekele BN, Yung WK, Fueyo J.
    Oncogene; 2004 Mar 11; 23(10):1821-8. PubMed ID: 15014451
    [Abstract] [Full Text] [Related]

  • 31. Overexpression of p53-related proteins predicts rapid growth rate of head and neck cancer.
    Edström S, Cvetkovska E, Westin T, Young C.
    Laryngoscope; 2001 Jan 11; 111(1):124-30. PubMed ID: 11192880
    [Abstract] [Full Text] [Related]

  • 32. E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer.
    Fukuda K, Abei M, Ugai H, Seo E, Wakayama M, Murata T, Todoroki T, Tanaka N, Hamada H, Yokoyama KK.
    Cancer Res; 2003 Aug 01; 63(15):4434-40. PubMed ID: 12907616
    [Abstract] [Full Text] [Related]

  • 33. ONYX-015 selectivity and the p14ARF pathway.
    McCormick F.
    Oncogene; 2000 Dec 27; 19(56):6670-2. PubMed ID: 11426653
    [Abstract] [Full Text] [Related]

  • 34. Clinical applications of the diagnosis of p53 alterations in squamous cell carcinoma of the head and neck.
    Lopez-Martinez M, Anzola M, Cuevas N, Aguirre JM, De-Pancorbo M.
    Med Oral; 2002 Dec 27; 7(2):108-20. PubMed ID: 11887018
    [Abstract] [Full Text] [Related]

  • 35. Virus-associated RNA I-deleted adenovirus, a potential oncolytic agent targeting EBV-associated tumors.
    Wang Y, Xue SA, Hallden G, Francis J, Yuan M, Griffin BE, Lemoine NR.
    Cancer Res; 2005 Feb 15; 65(4):1523-31. PubMed ID: 15735041
    [Abstract] [Full Text] [Related]

  • 36. E1A-induced apoptosis does not prevent replication of adenoviruses with deletion of E1b in majority of infected cancer cells.
    Rao XM, Tseng MT, Zheng X, Dong Y, Jamshidi-Parsian A, Thompson TC, Brenner MK, McMasters KM, Zhou HS.
    Cancer Gene Ther; 2004 Sep 15; 11(9):585-93. PubMed ID: 15338010
    [Abstract] [Full Text] [Related]

  • 37. [Treatment of head and neck squamous cell carcinoma by recombinant adenovirus-p53 combined with radiotherapy: a phase II clinical trial of 42 cases].
    Zhang SW, Xiao SW, Liu CQ, Sun Y, Su X, Li DM, Xu G, Cai Y, Zhu GY, Xu B, Lü YY.
    Zhonghua Yi Xue Za Zhi; 2003 Dec 10; 83(23):2023-8. PubMed ID: 14703408
    [Abstract] [Full Text] [Related]

  • 38. p53 apoptotic response to DNA damage dependent on bcl2 but not bax in head and neck squamous cell carcinoma lines.
    Crowe DL, Sinha UK.
    Head Neck; 2006 Jan 10; 28(1):15-23. PubMed ID: 16302195
    [Abstract] [Full Text] [Related]

  • 39. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.
    Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F.
    Science; 1996 Oct 18; 274(5286):373-6. PubMed ID: 8832876
    [Abstract] [Full Text] [Related]

  • 40. Adenoviral p53 gene therapy in squamous cell cancer of the head and neck region.
    Edelman J, Edelman J, Nemunaitis J.
    Curr Opin Mol Ther; 2003 Dec 18; 5(6):611-7. PubMed ID: 14755887
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.